Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 27 studies | 26% ± 13% | |
CD16-positive, CD56-dim natural killer cell, human | 13 studies | 29% ± 9% | |
mucosal invariant T cell | 12 studies | 32% ± 11% | |
mature NK T cell | 10 studies | 22% ± 8% | |
CD16-negative, CD56-bright natural killer cell, human | 9 studies | 26% ± 7% | |
gamma-delta T cell | 7 studies | 23% ± 7% | |
CD8-positive, alpha-beta T cell | 6 studies | 24% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 6 studies | 27% ± 7% | |
T cell | 4 studies | 27% ± 4% | |
lymphocyte | 4 studies | 36% ± 15% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 22% ± 5% | |
B cell | 3 studies | 18% ± 1% | |
CD4-positive, alpha-beta T cell | 3 studies | 27% ± 13% | |
effector memory CD4-positive, alpha-beta T cell | 3 studies | 22% ± 4% | |
innate lymphoid cell | 3 studies | 26% ± 8% |
Insufficient scRNA-seq data for expression of MYBL1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 92% | 250.13 | 2443 / 2642 | 100% | 4.47 | 702 / 705 |
lung | 99% | 620.84 | 572 / 578 | 88% | 3.13 | 1016 / 1155 |
breast | 86% | 209.61 | 394 / 459 | 95% | 10.18 | 1066 / 1118 |
uterus | 82% | 165.74 | 139 / 170 | 89% | 4.01 | 410 / 459 |
intestine | 91% | 277.78 | 883 / 966 | 65% | 1.68 | 344 / 527 |
esophagus | 66% | 115.76 | 955 / 1445 | 88% | 2.92 | 161 / 183 |
skin | 58% | 381.46 | 1049 / 1809 | 91% | 5.52 | 430 / 472 |
bladder | 81% | 167.90 | 17 / 21 | 64% | 2.23 | 323 / 504 |
stomach | 67% | 176.52 | 241 / 359 | 68% | 1.95 | 195 / 286 |
ovary | 46% | 71.93 | 82 / 180 | 89% | 2.62 | 381 / 430 |
kidney | 43% | 102.39 | 38 / 89 | 91% | 3.52 | 820 / 901 |
liver | 69% | 159.54 | 157 / 226 | 62% | 1.73 | 251 / 406 |
prostate | 81% | 215.37 | 198 / 245 | 49% | 0.81 | 247 / 502 |
thymus | 70% | 169.73 | 455 / 653 | 55% | 1.26 | 332 / 605 |
adrenal gland | 35% | 50.97 | 90 / 258 | 83% | 2.73 | 190 / 230 |
spleen | 100% | 1447.65 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1456.22 | 1334 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 3.21 | 41 / 45 |
adipose | 89% | 249.42 | 1075 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 9.65 | 25 / 29 |
peripheral blood | 82% | 804.27 | 763 / 929 | 0% | 0 | 0 / 0 |
heart | 81% | 217.34 | 698 / 861 | 0% | 0 | 0 / 0 |
pancreas | 3% | 5.51 | 10 / 328 | 74% | 1.98 | 132 / 178 |
eye | 0% | 0 | 0 / 0 | 40% | 0.73 | 32 / 80 |
muscle | 23% | 36.34 | 187 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0140543 | Biological process | positive regulation of piRNA transcription |
GO_0007283 | Biological process | spermatogenesis |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0000278 | Biological process | mitotic cell cycle |
GO_0030154 | Biological process | cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0007141 | Biological process | male meiosis I |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
Gene name | MYBL1 |
Protein name | Myb-related protein A (A-Myb) (Myb-like protein 1) V-myb myeloblastosis viral oncogene homolog (Avian)-like 1 MYB proto-oncogene like 1 |
Synonyms | AMYB |
Description | FUNCTION: Transcription factor that specifically recognizes the sequence 5'-YAAC[GT]G-3' . Acts as a master regulator of male meiosis by promoting expression of piRNAs: activates expression of both piRNA precursor RNAs and expression of protein-coding genes involved in piRNA metabolism (By similarity). The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons, which is essential for the germline integrity (By similarity). Transcriptional activator of SOX30 (By similarity). . |
Accessions | ENST00000524176.2 [P10243-2] ENST00000517885.5 Q495G0 P10243 ENST00000522677.8 [P10243-1] E7EWZ1 |